4D Molecular Therapeutics (NASDAQ:FDMT) Posts Earnings Results, Misses Estimates By $0.10 EPS

4D Molecular Therapeutics (NASDAQ:FDMT) announced its quarterly earnings data on Friday. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.10), Zacks reports.

4D Molecular Therapeutics Trading Up 1.1 %

Shares of NASDAQ:FDMT opened at $4.53 on Friday. The company has a market cap of $209.41 million, a price-to-earnings ratio of -1.59 and a beta of 2.81. 4D Molecular Therapeutics has a 12 month low of $4.20 and a 12 month high of $36.25. The company has a 50-day moving average price of $5.22 and a 200 day moving average price of $8.59.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. BMO Capital Markets downgraded shares of 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $40.00 to $15.00 in a report on Monday, January 13th. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, February 19th. Bank of America cut their price target on 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Chardan Capital lowered their price objective on 4D Molecular Therapeutics from $39.00 to $30.00 and set a “buy” rating on the stock in a research report on Tuesday, February 11th. Finally, Royal Bank of Canada cut their target price on 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating for the company in a research report on Thursday, November 14th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, 4D Molecular Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $32.13.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.